BC Week In Review | Aug 17, 2018
Company News

Almirall acquires U.S. dermatology products from Allergan

Almirall S.A. (Madrid:ALM) will acquire a portfolio of five dermatology products marketed in the U.S. from Allergan plc (NYSE:AGN) for $550 million in cash. The portfolio, which generated 1H18 sales of $70 million, includes acne...
BC Week In Review | Jan 5, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
BC Extra | Jan 4, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
BC Extra | Sep 14, 2016
Top Story

Allergan acquiring Vitae

Allergan plc (NYSE:AGN) is acquiring Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) for $21 per share in cash, or about $639 million. The price is a 159% premium to Vitae's close of $8.10 on Tuesday, before the deal...
BC Week In Review | Mar 7, 2016
Clinical News

Aczone dapsone topical gel regulatory update

FDA approved Allergan’s Aczone dapsone 7.5% topical gel to treat acne vulgaris in patients ages >=12. The company already markets Aczone 5% in the U.S. and plans to launch the new product in May. Aczone...
BioCentury | Nov 9, 2015
Strategy

Pfizer's growth spurt

Eighteen months ago, flat-to-flagging growth across Pfizer Inc .'s innovative and established products businesses suggested the pharma needed a major acquisition to shore up the units before it could move forward with a much-discussed potential...
BC Week In Review | Feb 14, 2011
Company News

Valeant Pharmaceuticals, Allergan sales and marketing update

Allergen granted Valeant's Biovail Laboratories International SRL subsidiary exclusive Canadian rights to Aczone dapsone topical gel 5% to treat acne vulgaris. Allergan will receive C$500,000 ($506,050) up front and is eligible for sales-based milestones. The...
BC Week In Review | May 18, 2009
Company News

Allergan, SkinMedica sales and marketing update

The companies will co-promote Allergan's Aczone dapsone 5% topical gel in the U.S. SkinMedica's sales force will call on pediatricians, while Allergan's will continue to target dermatologists. SkinMedica will receive a portion of sales above...
BC Week In Review | Jul 21, 2008
Company News

QLT, Allergan deal

Allergan’s Allergan Sales LLC subsidiary completed its previously announced acquisition of all worldwide assets related to QLT’s Aczone dapsone topical gel to treat acne vulgaris for $150 million in cash (see BioCentury, June 16). QLT...
BC Week In Review | Jun 16, 2008
Company News

QLT, Allergan deal

Allergan’s Allergan Sales LLC subsidiary paid $150 million in cash to QLT for all worldwide assets related to Aczone dapsone topical gel to treat acne vulgaris. The topical 5% dapsone gel is approved in the...
Items per page:
1 - 10 of 66